1. Signaling Pathways
  2. Epigenetics
  3. DNA Methyltransferase
  4. DNA Methyltransferase Isoform
  5. DNA Methyltransferase Inhibitor

DNA Methyltransferase Inhibitor

DNA Methyltransferase Inhibitors (37):

Cat. No. Product Name Effect Purity
  • HY-139664
    GSK-3685032
    Inhibitor 99.95%
    GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition.
  • HY-13765
    6-Thioguanine
    Inhibitor 98.01%
    6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC50s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.
  • HY-B0106
    Levetiracetam
    Inhibitor 99.90%
    Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent.
  • HY-A0084A
    Procainamide
    Inhibitor 99.69%
    Procainamide (Procaine amide) is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1), which reactivates the expression of tumor suppressor factors by demethylating tumor suppressor genes. Procainamide induces vacuolization in various cell types and reduces cell proliferation and migration. Procainamide relaxes airway smooth muscle by activating potassium channels. Procainamide can be used in cancer and arrhythmia research.
  • HY-117421A
    CM-579 trihydrochloride
    Inhibitor
    CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.
  • HY-161402
    METTL16-IN-1
    Inhibitor 99.22%
    METTL16-IN-1 (Compound 45) is a potent METTL16 inhibitor with an IC50 value of 1.7 μM and a Kd value of 1.35 μM.
  • HY-A0084
    Procainamide hydrochloride
    Inhibitor ≥98.0%
    Procainamide hydrochloride (Procaine amide hydrochloride) is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1), which reactivates the expression of tumor suppressor factors by demethylating tumor suppressor genes. Procainamide hydrochloride induces vacuolization in various cell types and reduces cell proliferation and migration. Procainamide hydrochloride relaxes airway smooth muscle by activating potassium channels. Procainamide hydrochloride can be used in cancer and arrhythmia research.
  • HY-162082
    METTL1-WDR4-IN-2
    Inhibitor 99.71%
    METTL1-WDR4-IN-2 (compound 6) is a selective methyltransferase Like 1 (METTL1)-WDR4 inhibitor with an IC50 of 41 μM. METTL1-WDR4-IN-2 shows remarkable selectivity against METTL3-14 and slightly selective also against METTL16.
  • HY-N2150
    Psammaplin A
    Inhibitor
    Psammaplin A, a marine metabolite, is a potent inhibitor of HDAC and DNA methyltransferases. Psammaplin A ia a highly potent and selective DAC1 inhibitor with an IC50 of 0.9 nM. Psammaplin A possess the antimicrobial effect on the Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Antitumor Activity.
  • HY-150249
    GSK3735967
    Inhibitor 99.71%
    GSK3735967 is an selective, reversible, non-nucleoside inhibitor of DNMT1 with an IC50 value of 40 nM. GSK3735967 contains a planar dicyanopyridine core that can specifically embed DNMT1 bound hemimethylated CpG dinucleotides. GSK3735967 has three binding sites, one of which can bind to histone H4K20me3.
  • HY-131991
    Benzyl selenocyanate
    Inhibitor ≥99.0%
    Benzyl selenocyanate is a chemopreventive agent for various chemically induced tumors in animal models at both the initiation and postinitiation stages. Benzyl selenocyanate is an inhibitor of DNA (cytosine-5)-methyltransferase (Mtase), with an with an IC50 of 8.4 µM.
  • HY-12310
    RSC133
    Inhibitor ≥98.0%
    RSC133 exhibits dual activity by inhibiting histone deacetylase and DNA methyltransferase. RSC133 effectively facilitates reprogramming of human somatic cells to pluripotent stem cells and supports the maintenance of an undifferentiated state of human pluripotent stem cells.
  • HY-123346
    SW155246
    Inhibitor 98.31%
    SW155246 is a DNA methyltransferase (DNMT1) selective inhibitor with IC50s of 1.2 and 38 μM for hDNMT1 and mDNMT3A, respectively. SW155246 can be used for the research of cancer and other diseases.
  • HY-13542
    Guadecitabine
    Inhibitor 98.0%
    Guadecitabine (SGI-110) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
  • HY-117421
    CM-579
    Inhibitor
    CM-579 is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.
  • HY-111644
    6-Methyl-5-azacytidine
    Inhibitor
    6-Methyl-5-azacytidine is a potent DNMT inhibitor.
  • HY-119390
    AA-CW236
    Inhibitor 99.86%
    AA-CW236 is a MGMT (O6-methylguanine DNA methyltransferase) inhibitor. AA-CW236 targets MGMT active site Cys145 for covalent modification.
  • HY-133030
    DNMT-IN-1
    Inhibitor
    DNMT-IN-1 is a potent DNMT inhibitor with an EC50 value of 3.2 µM. DNMT-IN-1 shows antiproliferative active.
  • HY-163614
    SARS-CoV-2-IN-87
    Inhibitor
    SARS-CoV-2-IN-87 (compound 138968421) is a potent inhibitor of methyltransferases (nsp14 and nsp16) of SARS-CoV-2.
  • HY-B0106S
    Levetiracetam-d6
    Inhibitor
    Levetiracetam-d6 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent[1][2].